PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
-
Swiatek races into Toronto semis as Svitolina battles through
-
Oil prices rise further as hopes for Hormuz deal fade
-
'Big Four' bowlers back as ageing Australia begin gruelling run
-
One year after Putin-Trump summit, 'spirit of Anchorage' dissipated
-
AI's hunger for power sparks US private gas plant boom
-
Farage vs Count Binface: What to know about UK snap poll
-
Memphis AI data center fuels pollution fight in Black neighborhood
-
Torment of Afghan fathers as daughters deprived of education
-
Ceuta leader wants migrant detention centre after influx
-
Return of displaced Syrian Kurds to hometown suspended after violence
-
Colombia scrambles to find survivors as quake kills 111
-
Swiatek races past Shnaider into Toronto semi-finals
-
Rain postponements wreck Montreal Masters schedule
-
Meta pushes global AI vision amid race with OpenAI, Anthropic and China
-
Notts Forest owner Marinakis sues Palace over gun banner - reports
-
US judge ends graft case against India's Adani
-
Koech gets three-year ban, stripped of US 1,500m title
-
Anderson retires after 10 MLB seasons after 'too much pain'
-
Sensational Ingebrigtsen back with more European gold
-
Colombia in state of emergency as quake kills 111
-
'A scare': Brazil player leaps into tunnel in joy over goal
-
Britain's Amy Hunt wins European women's 100m gold
-
USA Swimming CFO Hilliard arrested for alleged theft
-
Trump order pushes for overhaul of childhood vaccine schedule
-
Trump insists Netanyahu relationship 'very good' despite Gaza rift
-
Global stocks mixed while oil prices jump on Hormuz
-
Ingebrigtsen delivers masterclass for seventh European athletics gold
-
Turkey MPs back historic law on reintegrating Kurdish militants
-
Colombia declares state of emergency after quake kills 111
-
'Dreams disappear' as Gaza students await evacuation to Italy
-
Golden relay double for Britain at Europeans as Marchand takes silver
-
Third European gold for Schilder in women's shot put
-
Barcelona's Araujo heads to Liverpool on loan
-
Golden relay double for Britain at Europeans as Marchand settles for silver
-
Tupac Shakur murder trial begins 30 years after rapper's death
-
US had hottest month on record in July
-
Russia bars only anti-war party from elections
-
Colombia quake leaves 69 dead, with more trapped under rubble
-
Boeing to divest tech ventures for stake in air-taxi startup
-
Bookmap Announces Partnership with Plus500 to Expand Futures Trading Access
-
Major quake rocks Colombia and neighbors, 18 confirmed dead
-
Barcelona turn down PSG offer for Torres
-
Brazil aircraft maker Embraer raises outlook after record revenue
-
Buildings collapse as major quake rocks Colombia and neighbors
-
Drought forces water restrictions across nearly 70 percent of France
-
Meta releases new AI model as Zuckerberg lays out vision
-
Europe wary as gas stocks languish at lows while winter looms
-
Freedom Holding Corp. Reports 40% Increase in Quarterly Revenue to $732.5 Million
-
OFunded Enters the Prop Trading Market With Broker-Backed Infrastructure From OFinancial Markets
-
What next for beleaguered FIFA president Infantino?
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
E.Ramalho--PC
